198 related articles for article (PubMed ID: 33202491)
1. [Association of Breg cells and Treg cells with the clinical effects of Infliximab in the treatment of Chinese patients with Crohn's disease].
Lin QR; Xia XP; Cai XN; Hu DY; Shao XX; Xia SL; Jiang Y
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3303-3308. PubMed ID: 33202491
[No Abstract] [Full Text] [Related]
2. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
[TBL] [Abstract][Full Text] [Related]
3. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
[TBL] [Abstract][Full Text] [Related]
5. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
6. A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease.
Peng Z; Xu D; Li Y; Liu X; Li F; Peng Y
Ann Med; 2023 Dec; 55(1):2236011. PubMed ID: 37477647
[TBL] [Abstract][Full Text] [Related]
7. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
Li Z; Arijs I; De Hertogh G; Vermeire S; Noman M; Bullens D; Coorevits L; Sagaert X; Schuit F; Rutgeerts P; Ceuppens JL; Van Assche G
Inflamm Bowel Dis; 2010 Aug; 16(8):1299-310. PubMed ID: 20196149
[TBL] [Abstract][Full Text] [Related]
9. Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
11. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells.
Kessel A; Haj T; Peri R; Snir A; Melamed D; Sabo E; Toubi E
Autoimmun Rev; 2012 Jul; 11(9):670-7. PubMed ID: 22155204
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
13. Changes in Treg and Breg cells in a healthy pediatric population.
Luo Y; Acevedo D; Vlagea A; Codina A; García-García A; Deyà-Martínez A; Martí-Castellote C; Esteve-Solé A; Alsina L
Front Immunol; 2023; 14():1283981. PubMed ID: 38077340
[TBL] [Abstract][Full Text] [Related]
14. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
Ricciardelli I; Lindley KJ; Londei M; Quaratino S
Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
[TBL] [Abstract][Full Text] [Related]
15. Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease.
Di Sabatino A; Biancheri P; Piconese S; Rosado MM; Ardizzone S; Rovedatti L; Ubezio C; Massari A; Sampietro GM; Foschi D; Porro GB; Colombo MP; Carsetti R; MacDonald TT; Corazza GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1891-7. PubMed ID: 20848485
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic Analysis of CD4+ Treg, CD8+ Treg, and Breg Cells in Adult Common Variable Immunodeficiency Patients.
Yesillik S; Agrawal S; Gollapudi SV; Gupta S
Int Arch Allergy Immunol; 2019; 180(2):150-158. PubMed ID: 31284281
[TBL] [Abstract][Full Text] [Related]
17. Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein.
Takeyama H; Mizushima T; Iijima H; Shinichiro S; Uemura M; Nishimura J; Hata T; Takemasa I; Yamamoto H; Doki Y; Mori M
Dig Dis Sci; 2015 Nov; 60(11):3418-23. PubMed ID: 26077975
[TBL] [Abstract][Full Text] [Related]
18. Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure.
Edlund H; Grisic AM; Steenholdt C; Ainsworth MA; Brynskov J; Huisinga W; Kloft C
Ther Drug Monit; 2019 Apr; 41(2):235-242. PubMed ID: 30883516
[TBL] [Abstract][Full Text] [Related]
19. [Mucosal healing in different intestinal segments in patients receiving infliximab treatment for small bowel Crohn's disease].
Zhu ZH; Qiu C; Zhang M; Chen Z; Xiang C; Wang XY
Nan Fang Yi Ke Da Xue Xue Bao; 2017 Jan; 37(1):44-48. PubMed ID: 28109097
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells.
Dige A; Hvas CL; Deleuran B; Kelsen J; Bendix-Struve M; Dahlerup JF; Agnholt J
Scand J Gastroenterol; 2011 Oct; 46(10):1206-14. PubMed ID: 21793633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
